Reverse DCF
What growth does the market imply for TORNTPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
17.3% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹4,571
Historical Growth
10.0%
FCF Yield
1.52%
Price / FCF
66.0x
Plain English
To justify today's price of ₹4571.20, TORNTPHARM.NS needs to grow its free cash flow at 17.3% per year for the next 10 years. That is 7.3% faster than its historical growth rate of 10.0%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 8.6% | ₹2,015 | -55.9% |
| GDP rate | 10.0% | ₹2,308 | -49.5% |
| Historical | 10.0% | ₹2,314 | -49.4% |
| Implied | 17.3% | ₹4,571 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 10.0% growth, the model values TORNTPHARM at ₹2,314, below today's ₹4,571.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.